Projects per year
Personal profile
Biography
Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University.
Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer.
He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics.
Fingerprint Dive into the research topics where Howard Gurney is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 7 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT-101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma
Sabanathan, D., Chapman, N., Butala, R. & Gurney, H.
16/05/19 → 15/05/24
Project: Other
MISC_UniCanberra: Research into and Testing of Epigenetic based Biomarkers and companion therapeutics.
Gurney, H. & Cunningham, J.
1/04/19 → 30/04/20
Project: Other
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Gurney, H., Chapman, N. & Butala, R.
28/02/19 → 27/02/24
Project: Other
Misc_Novotech: A Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study Comparing CB‐839 in Combination with Cabozantinib (CB‐Cabo) vs. Placebo with Cabozantinib (Pbo‐Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Gurney, H. & Cunningham, J.
17/07/18 → 5/06/23
Project: Other
MISC_Covance Chiltern: A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients with Advanced Solid Tumors
Gurney, H., Butala, R. & Cunningham, J.
16/07/18 → 15/07/23
Project: Other
Research Outputs
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer
Sternberg, C. N., Saad, F., Graff, J. N., Peer, A., Vaishampayan, U. N., Leung, E., Rosenbaum, E., Gurney, H., Epstein, R. J., Davis, I. D., Wu, B., Trandafir, L., Wagner, V. J. & Hussain, M., 1 Feb 2020, In : Annals of Oncology. 31, 2, p. 257-265 9 p.Research output: Contribution to journal › Article
Open Access
File
1
Citation
(Scopus)
Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics
Nath, C. E., Trotman, J., Nivison-Smith, I., Gurney, H., Zeng, L., Presgrave, P., Tiley, C., Joshua, D., Kerridge, I., McLachlan, A. J. & Shaw, P. J., 21 Feb 2020, In : Bone Marrow Transplantation.Research output: Contribution to journal › Letter
The adverse effects of androgen deprivation therapy in prostate cancer and the benefits and potential anti-oncogenic mechanisms of progressive resistance training
Lam, T., Birzniece, V., McLean, M., Gurney, H., Hayden, A. & Cheema, B. S., 1 Dec 2020, In : Sports Medicine - Open. 6, 1, p. 1-14 14 p., 13.Research output: Contribution to journal › Review article
Open Access
File
A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy
Lam, T., McLean, M., Hayden, A., Poljak, A., Cheema, B., Gurney, H., Stone, G., Bahl, N., Reddy, N., Shahidipour, H. & Birzniece, V., 1 May 2019, In : Endocrine Connections. 8, 5, p. 605-615 11 p.Research output: Contribution to journal › Article
Open Access
File
2
Downloads
(Pure)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., Hawkins, R., Ravaud, A., Alekseev, B., Staehler, M., Uemura, M., De Giorgi, U., Mellado, B., Porta, C., Melichar, B., Gurney, H. & 12 others, , 15 Jun 2019, In : The Lancet. 393, 10189, p. 2404-2415 12 p.Research output: Contribution to journal › Article
65
Citations
(Scopus)